GlassScriptPhysician profile
Lindsey E Sweat
NPI 1457733842
$8,913.54
in general payments reported to CMS, 2019-2025
45 companies · $1,829 in 2025
The $1,829 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $528 · 2020: $752 · 2021: $1,635 · 2022: $893 · 2023: $1,563 · 2024: $1,714 · 2025: $1,829.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,011 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,010.88 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,097.49 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $868.31 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $821.95 | 2020-2025 | Vraylar, Ubrelvy, Qulipta |
| Glaxosmithkline, LLC. | $666.05 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $630.11 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Astellas Pharma US INC | $493.37 | 2019-2025 | Veozah, Myrbetriq |
| Amgen INC. | $484.45 | 2019-2025 | Repatha, Otezla, Repatha |
| Ferring Pharmaceuticals INC. | $415.52 | 2019-2025 | Euflexxa |
| Otsuka America Pharmaceutical, INC. | $359.23 | 2022-2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $352.24 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $292.24 | 2019-2023 | Xarelto |
| Pfizer INC. | $202.12 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $194.42 | 2019-2025 | Xifaxan, Trulance |
| Exact Sciences Corporation | $171.50 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Merck Sharp & Dohme LLC | $160.88 | 2019-2024 | Gardasil 9, Gardasil, Capvaxive |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $135.04 | 2021-2025 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $132.13 | 2024-2025 | |
| Biohaven Pharmaceuticals, INC. | $112.77 | 2020-2021 | |
| Abbott Laboratories | $94.57 | 2022-2024 | Freestyle Libre 3 |
| E.R. Squibb & Sons, L.L.C. | $90.98 | 2023-2024 | Eliquis, Camzyos |
| Harmony Biosciences LLC | $87.08 | 2025 | |
| Phathom Pharmaceuticals, INC. | $76.11 | 2024-2025 | Voquezna |
| Sunovion Pharmaceuticals INC. | $74.64 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $72.98 | 2019-2025 | Trintellix |
| Idorsia Pharmaceuticals US INC | $71.60 | 2022-2024 | Quviviq |
| Boston Scientific Corporation | $69.48 | 2025 | General - Pain Management |
| Amarin Pharma, INC. | $67.67 | 2019-2021 | |
| Insulet Corporation | $55.85 | 2024-2025 | Omnipod |
| Pacira Pharmaceuticals Incorporated | $53.64 | 2022-2023 | Exparel, Iovera, Zilretta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.63 | 2024-2025 | Jardiance |
| Biohaven Pharmaceutical Holding Company LTD. | $49.14 | 2022 | |
| Vertos Medical, INC. | $47.07 | 2021 | |
| Almatica Pharma LLC | $42.73 | 2024 | Teriparatide |
| Ucb, INC. | $42.71 | 2021-2025 | Bimzelx |
| Nevro Corp. | $41.33 | 2020-2022 | |
| Medtronic, INC. | $38.87 | 2022-2023 | Intellis Adaptivestim |
| Nalu Medical, INC. | $37.70 | 2023-2024 | Nalu Neurostimulation System |
| Sanofi Pasteur INC. | $33.22 | 2021-2023 | |
| Axsome Therapeutics, INC. | $21.57 | 2025 | Auvelity |
| Sanofi-Aventis U.S. LLC | $20.79 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $18.13 | 2020 | |
| Xeris Pharmaceuticals, INC. | $17.99 | 2021 | |
| Convatec INC. | $16.98 | 2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.01 | 2025 | Caplyta |
| Bioventus LLC | $12.25 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lindsey Sweat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.